Darolutamide for new prostate cancer that spread
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how well darolutamide and similar drugs work for men whose prostate cancer has just spread to other parts of the body. It aims to understand real-world outcomes in urology clinics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man with prostate cancer that has just spread to other parts of the body (metastatic).
- You started taking a type of hormone therapy called darolutamide or a similar drug within 90 days of diagnosis.
- You are 18 years or older when you started the therapy.
- You also started hormone therapy (ADT) or chemotherapy (docetaxel) around the same time.
- You have no history of other cancers (except non-melanoma skin cancer) and have not used certain other cancer treatments before starting the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug darolutamide for men whose prostate cancer has spread and is no longer controlled by standard hormone therapy. It may be an option if you've already had certain hormone treatments for at least 12 months but your cancer is still progressing.
This trial tests a combination of two drugs (darolutamide plus hormone therapy) along with a low dose of chemotherapy (docetaxel) for men whose prostate cancer has spread to other parts of the body. It aims to see if this combined approach is safe and effective.
This study tests combining targeted radiation therapy (guided by special imaging) with a hormone-blocking medication called darolutamide in men with prostate cancer that has spread to other parts of the body. The goal is to see if this combination works better than standard treatment alone.
This study looks at how well a drug called darolutamide (a type of hormone therapy) works in everyday medical practice for men with advanced prostate cancer that has spread. It is for men who are already starting this treatment with their doctor and will help doctors understand how it works in real life.
This study looks at how certain drugs (darolutamide, enzalutamide, apalutamide, or abiraterone) that block male hormones are used to treat men with prostate cancer that has spread. It aims to understand real-world treatment patterns in Australia.
This study looks at how safe and effective the combination of darolutamide (a tablet), hormone therapy (ADT), and chemotherapy (docetaxel) is for Japanese men with prostate cancer that has spread in a limited way (low volume). It observes people in regular medical care, not in a research setting.
Hear when a new Prostatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.